DMA Diamedica Therapeutics

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES/


DiaMedica Inc. (TSX VENTURE:DMA), announced today that it has filed a final
short form prospectus, dated December 13, 2013 relating to its previously
announced offering (the "Offering") of units of the Company (the "Units"). The
Company will offer 2,778,000 Units at a price of $0.90 per Unit for gross
proceeds to the Company of $2,500,200. The Offering is being placed on a
commercially reasonable efforts agency basis by Jordan Capital Markets Inc. (the
"Agent"). The Company has granted to the Agent an option exercisable in whole or
in part at any time within 30 days of the closing date of the Offering, to
increase the number of Units offered by up to 15% on the same terms and
conditions.


DiaMedica intends to use the net proceeds from the offering for research and
development, including a Phase II clinical trial for Type 2 diabetes, for
manufacturing activities in support of such research and development programs
and for working capital and general and administrative purposes as described in
the prospectus.


Each Unit will consist of one common share in the capital stock of DiaMedica (a
"Common Share") and one half of one common share purchase warrant (each whole
warrant, a "Warrant"). Each Warrant will entitle the holder thereof to purchase
one additional Common Share for the price of $1.10 within two years from the
closing date of the Offering, subject to an acceleration of the expiry date of
such Warrants in certain circumstances as more particularly described in the
Prospectus.


The Company has received the conditional approval of the TSX Venture Exchange
(the "Exchange") for the listing of Common Shares forming part of the Offering.
Listing is subject to DiaMedica satisfying all requirements of the Exchange.


The closing of the Offering is anticipated to take place on or about December
20, 2013, or such other date as the Agent and DiaMedica may determine.


About DiaMedica

DiaMedica Inc. (TSX VENTURE:DMA) is a biotechnology company developing
first-in-class treatments for the treatment of diabetes. DiaMedica's lead
compound, DM-199, is a recombinant human protein for the treatment of both Type
1 and Type 2 diabetes and their complications. The Company is also developing
the first therapeutic GPCR agonist monoclonal antibody, DM-204, for the
treatment of Type 2 diabetes and cardiovascular disease. DiaMedica's shares
trade on the Toronto Stock Exchange Venture (TSX VENTURE:DMA). For more
information please visit www.diamedica.com.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward- looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward- looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this News
Release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica
Rick Pauls
President and CEO
763-710-4455
info@diamedica.com


DiaMedica
One Carlson Parkway, Suite 124
Minneapolis, MN
www.diamedica.com

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024